908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
Last trade$9.11
Day change-$0.085 (-0.92%)
Day range$8.82 – $9.27
Volume137,102
Market cap$382M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$382.14M
Price / earnings
—
Price / book
2.55×
Price / sales
5.81×
EV / sales
4.84×
EV / EBITDA
-19.28×
Profitability
Earnings per share
-$0.58
Return on assets
-12.17%
Return on equity
-16.19%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.43×
Quick ratio
4.84×
Cash ratio
2.56×
Cash flow
Price / cash flow
132.5×
Price / free cash flow
145.69×
Free cash flow
$2.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MASS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$18.95M
$16.07M
$13.38M
$17.38M
$14.01M
$13.04M
$11.78M
$14.34M
Cost of revenue
$8.93M
$7.73M
$6.5M
$8.23M
$6.65M
$6.66M
$6.24M
$7.67M
Gross profit
$10.02M
$8.34M
$6.88M
$9.15M
$7.36M
$6.37M
$5.54M
$6.67M
Selling, general and administrative
$11.98M
$11.11M
$9.91M
$8.82M
$9.13M
$10.34M
$10.24M
$10.46M
Research and development
$3.82M
$3.6M
$3.47M
$3.5M
$3.84M
$4.41M
$3.83M
$3.9M
Total operating expenses
$15.49M
$14.71M
$19.77M
$6.06M
$23.68M
$14.74M
$16.57M
$23.42M
Operating income
-$5.48M
-$6.37M
-$12.88M
$3.09M
-$16.32M
-$8.37M
-$11.03M
-$16.75M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.63M
-$11.95M
-$11.96M
$4.21M
-$14.88M
-$12.84M
-$9.84M
-$16.02M
Income taxes
-$50K
-$54K
$0
-$166K
$29K
$71K
$0
$0
Net income
-$4.58M
-$11.89M
-$11.96M
$4.17M
-$14.98M
-$13.31M
$43.6M
-$19.45M
Net income attributable to common shareholders
-$4.58M
-$11.89M
-$11.96M
$4.17M
-$14.98M
-$13.31M
$43.6M
-$19.45M
EBITDA
-$3.98M
-$5.01M
-$11.75M
$4.2M
-$15.23M
-$7.4M
-$9.74M
-$5.18M
Basic earnings per share
-$0.11
-$0.32
-$0.32
$0.12
-$0.41
-$0.37
$1.23
-$0.56
Diluted earnings per share
-$0.11
-$0.32
-$0.32
$0.12
-$0.41
-$0.37
$1.23
-$0.56
Recent news
Company coverage with links to the original publishers.
908 Devices Inc. (MASS) beat earnings expectations with a loss of $0.11 per share versus consensus estimate of $0.16 loss, representing a 31.25% earnings surprise. Revenue of $18.95 million also surpassed estimates by 2.09%. The stock has gained 119.2% year-to-date, significantly outperforming the S&P 500's 10.3% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Orthofix (OFIX) shares surged 11% on investor optimism ahead of its third quarter 2026 financial results expected on November 9. The medical device maker is projected to report quarterly earnings of $0.11 per share (down 45% year-over-year) with revenues of $210.43 million (up 2.3%). However, analysts note the stock's recent gains may lack sustainability as consensus EPS estimates have remained unchanged over the past 30 days, and stocks typically require positive earnings estimate revisions to maintain upward momentum.
Integer Holdings (ITGR) reported Q3 2026 earnings of $1.34 per share, missing the consensus estimate of $1.65 and down from $1.79 year-ago. Revenue of $449.66 million also fell short of expectations and declined from $467.69 million year-over-year. The company received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions. Despite outperforming the S&P 500 by 61.4% year-to-date, the Medical-Instruments industry remains in the bottom 40% of Zacks-ranked industries.
908 Devices reported Q2 2025 revenue of $13.0 million, a 14% year-over-year increase, but experienced margin pressures and widened net losses. The company continues strategic investments and restructuring while targeting EBITDA break-even in Q4 2025.
908 Devices, a chemical analysis device maker, saw its stock rise over 18% this week after announcing a deal with the Romanian Customs Authority to deploy 27 of its MX908 devices throughout the organization. The deal, facilitated through an EU program, enhances 908 Devices' reputation and could lead to new clients.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.